{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:29:25Z","timestamp":1792625365131,"version":"4.5.0"},"reference-count":136,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.cgh.2022.01.024","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T18:32:45Z","timestamp":1643826765000},"page":"2175-2184.e19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Tegaserod: What\u2019s Old Is New Again"],"prefix":"10.1016","volume":"20","author":[{"given":"Gregory S.","family":"Sayuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3206-6704","authenticated-orcid":false,"given":"Jan","family":"Tack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2022.01.024_bib1","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1053\/j.gastro.2016.02.032","article-title":"Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV","volume":"150","author":"Drossman","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.01.024_bib2","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1053\/j.gastro.2016.02.031","article-title":"Bowel disorders","volume":"150","author":"Mearin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.01.024_bib3","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ajg.2012.131","article-title":"Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis","volume":"107","author":"Lovell","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.01.024_bib4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1053\/j.gastro.2020.04.014","article-title":"Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study","volume":"160","author":"Sperber","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.01.024_bib5","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1111\/j.1365-2036.2005.02463.x","article-title":"Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact","volume":"21","author":"Hungin","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.01.024_bib6","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1053\/gast.2000.16484","article-title":"The impact of irritable bowel syndrome on health-related quality of life","volume":"119","author":"Gralnek","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.01.024_bib7","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1572-0241.2001.03537.x","article-title":"Assessment of utilities and health-related quality of life in patients with chronic liver disease","volume":"96","author":"Younossi","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.01.024_bib8","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1097\/00042737-200111000-00011","article-title":"Impact of irritable bowel syndrome on personal relationships and working practices","volume":"13","author":"Silk","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.01.024_bib9","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41395-018-0262-x","article-title":"Work productivity and activity impairment in irritable bowel syndrome (IBS): a multifaceted problem","volume":"113","author":"Frandemark","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.01.024_bib10","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1572-0241.2003.07296.x","article-title":"Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective","volume":"98","author":"Longstreth","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.01.024_bib11","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1365-2036.2007.03370.x","article-title":"Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain","volume":"26","author":"Nyrop","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 2","key":"10.1016\/j.cgh.2022.01.024_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41395-018-0084-x","article-title":"American College of Gastroenterology Monograph on management of irritable bowel syndrome","volume":"113","author":"Ford","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.01.024_bib13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1517\/13543784.2013.761205","article-title":"The use of psychotropic drugs in irritable bowel syndrome","volume":"22","author":"Dekel","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.cgh.2022.01.024_bib14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41395-018-0222-5","article-title":"Effect of antidepressants and psychological therapies in irritable bowel syndrome: an updated systematic review and meta-analysis","volume":"114","author":"Ford","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.01.024_bib15","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1007\/s12325-017-0633-5","article-title":"The Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Chronic Idiopathic Constipation (BURDEN-CIC) study: results of an online questionnaire","volume":"34","author":"Harris","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.cgh.2022.01.024_bib16","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s12325-018-0733-x","article-title":"Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Irritable Bowel Syndrome with Constipation (BURDEN IBS-C) study: results of an online questionnaire","volume":"35","author":"Quigley","year":"2018","journal-title":"Adv Ther"},{"key":"10.1016\/j.cgh.2022.01.024_bib17","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/17512433.2019.1620104","article-title":"Use of prucalopride in adults with chronic idiopathic constipation","volume":"12","author":"Vijayvargiya","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.cgh.2022.01.024_bib18","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1358\/dot.2020.56.3.3115214","article-title":"Tenapanor for constipation-predominant irritable bowel syndrome","volume":"56","author":"Siddiqui","year":"2020","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.cgh.2022.01.024_bib19","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/j.1572-0241.2008.01808.x","article-title":"Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial","volume":"103","author":"Chey","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.01.024_bib20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.14309\/ajg.0000000000001036","article-title":"ACG Clinical Guideline: management of irritable bowel syndrome","volume":"116","author":"Lacy","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.01.024_bib21","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2036.2012.05011.x","article-title":"Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders","volume":"35","author":"Tack","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.01.024_bib22","first-page":"79","article-title":"Tegaserod maleate (Zelnorm) for IBS with constipation","volume":"44","year":"2002","journal-title":"Med Lett Drugs Ther"},{"key":"10.1016\/j.cgh.2022.01.024_bib23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/00002018-200427040-00002","article-title":"Benefit-risk assessment of tegaserod in irritable bowel syndrome","volume":"27","author":"Lea","year":"2004","journal-title":"Drug Saf"},{"key":"10.1016\/j.cgh.2022.01.024_bib24","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1503\/cmaj.1040882","article-title":"Tegaserod (Zelnorm) for irritable bowel syndrome: reports of serious diarrhea and intestinal ischemia","volume":"170","author":"Wooltorton","year":"2004","journal-title":"CMAJ"},{"key":"10.1016\/j.cgh.2022.01.024_bib25","first-page":"112","article-title":"Tegaserod: withdrawal from the world market. A treatment for constipation with cardiovascular adverse effects","volume":"17","year":"2008","journal-title":"Prescrire Int"},{"key":"10.1016\/j.cgh.2022.01.024_bib26","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.2146\/news070044","article-title":"Novartis suspends tegaserod sales at FDA's request","volume":"64","author":"Thompson","year":"2007","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.cgh.2022.01.024_bib27","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1592\/phco.24.5.526.33351","article-title":"Tegaserod-induced myocardial infarction: case report and hypothesis","volume":"24","author":"Busti","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cgh.2022.01.024_bib28","first-page":"72","article-title":"In brief: Tegaserod (Zelnorm) returns","volume":"61","year":"2019","journal-title":"Med Lett Drugs Ther"},{"key":"10.1016\/j.cgh.2022.01.024_bib29","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1111\/j.1365-2982.2010.01613.x","article-title":"Influence of tegaserod on proximal gastric tone and on the perception of gastric distention in functional dyspepsia","volume":"23","author":"Tack","year":"2011","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.cgh.2022.01.024_bib30","first-page":"71","article-title":"A\u00a0clinical audit of the efficacy of tegaserod as a prokinetic agent in the intensive care unit","volume":"10","author":"Deane","year":"2008","journal-title":"Crit Care Resusc"},{"key":"10.1016\/j.cgh.2022.01.024_bib31","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.cgh.2006.01.014","article-title":"Effect of tegaserod on esophageal pain threshold, regurgitation, and symptom relief in patients with functional heartburn and mechanical sensitivity","volume":"4","author":"Rodriguez-Stanley","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.01.024_bib32","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1177\/0091270003251823","article-title":"Tegaserod pharmacokinetics are similar in patients with severe renal insufficiency and in healthy subjects","volume":"43","author":"Swan","year":"2003","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.cgh.2022.01.024_bib33","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2165\/00003088-200241130-00002","article-title":"Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity","volume":"41","author":"Appel-Dingemanse","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cgh.2022.01.024_bib34","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/sj.bjp.0707118","article-title":"Differences between the abilities of tegaserod and motilin receptor agonists to stimulate gastric motility in\u00a0vitro","volume":"150","author":"Jarvie","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cgh.2022.01.024_bib35","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/j.1365-2036.2006.03090.x","article-title":"The effects of tegaserod on oesophageal function and bolus transport in healthy volunteers: studies using concurrent high-resolution manometry and videofluoroscopy","volume":"24","author":"Fox","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.01.024_bib36","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1046\/j.1365-2036.2001.01103.x","article-title":"Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects","volume":"15","author":"Degen","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.01.024_bib37","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0016-5085(00)70251-4","article-title":"Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome","volume":"118","author":"Prather","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.01.024_bib38","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1046\/j.1365-2036.2000.00854.x","article-title":"The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease","volume":"14","author":"Kahrilas","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.01.024_bib39","article-title":"itration regimen indicates partial 5-HT4 agonist HTF 919 improves symptoms of constipation predominant irritable bowel syndrome (C-IBS) [abstract]","volume":"59","author":"Hamling","year":"1998","journal-title":"Digestion"},{"key":"10.1016\/j.cgh.2022.01.024_bib40","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1046\/j.1365-2036.2001.01094.x","article-title":"Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation","volume":"15","author":"Muller-Lissner","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.01.024_bib41","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1046\/j.1365-2036.2002.01372.x","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation","volume":"16","author":"Novick","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.01.024_bib42","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S0895-4356(03)00027-1","article-title":"Subject's Global Assessment of Relief: an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials","volume":"56","author":"Muller-Lissner","year":"2003","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.cgh.2022.01.024_bib43","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/gut.52.5.671","article-title":"An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome","volume":"52","author":"Kellow","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2022.01.024_bib44","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/00365520310006748","article-title":"A\u00a0double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome","volume":"39","author":"Nyhlin","year":"2004","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.01.024_bib45","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/j.1572-0241.2002.05692.x","article-title":"Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms","volume":"97","author":"Fidelholtz","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.01.024_bib46","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1136\/gut.2005.070789","article-title":"A\u00a0randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation","volume":"54","author":"Tack","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2022.01.024_bib47","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s002280050255","article-title":"A\u00a0comparison of two cohort studies evaluating the safety of cisapride: prescription-event monitoring and a large phase IV study","volume":"52","author":"Wager","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cgh.2022.01.024_bib48","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1001\/jama.284.23.3036","article-title":"Contraindicated use of cisapride: impact of food and drug administration regulatory action","volume":"284","author":"Smalley","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2022.01.024_bib49","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1161\/01.CIR.97.2.204","article-title":"Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval","volume":"97","author":"Drolet","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.cgh.2022.01.024_bib50","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jama.286.13.1607","article-title":"Coprescribing and codispensing of cisapride and contraindicated drugs","volume":"286","author":"Jones","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2022.01.024_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00210-011-0694-y","article-title":"Tegaserod in the treatment of constipation-predominant irritable bowel syndrome. Do the risks outweigh the benefits?","volume":"385","author":"Wood","year":"2012","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.cgh.2022.01.024_bib52","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1053\/j.gastro.2007.04.057","article-title":"Desperately seeking serotonin... A commentary on the withdrawal of tegaserod and the state of drug development for functional and motility disorders","volume":"132","author":"Pasricha","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.01.024_bib53","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/j.1572-0241.2008.01815.x","article-title":"The FDA's decision-making process: isn't it time to temper the principle of protective paternalism?","volume":"103","author":"Brandt","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.01.024_bib54","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/j.1572-0241.2006.00988.x","article-title":"Efficacy of tegaserod in chronic constipation in men","volume":"102","author":"Fried","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.01.024_bib55","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1111\/j.1572-0241.2002.05986.x","article-title":"Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects","volume":"97","author":"Morganroth","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.01.024_bib56","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1365-2710.2002.00426.x","article-title":"A\u00a0systematic review of tegaserod for the treatment of irritable bowel syndrome","volume":"27","author":"Jones","year":"2002","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.cgh.2022.01.024_bib57","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/1074248409340158","article-title":"Lack of association of tegaserod with adverse cardiovascular outcomes in a matched case-control study","volume":"14","author":"Anderson","year":"2009","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.01.024_bib58","first-page":"e194","article-title":"Safety and efficacy of tegaserod therapy in patients with irritable bowel syndrome or chronic constipation","volume":"17","author":"Al-Judaibi","year":"2010","journal-title":"Can J Clin Pharmacol"},{"key":"10.1016\/j.cgh.2022.01.024_bib59","article-title":"Re-evaluation of the cardiovascular safety profile of tegaserod: a review of the clinical data","author":"Lacy","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.01.024_bib60","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1592\/phco.2005.25.11.1684","article-title":"Ischemic colitis, irritable bowel syndrome, and tegaserod--an alternative viewpoint","volume":"25","author":"Shetzline","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cgh.2022.01.024_bib61","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2165\/00002018-200730070-00003","article-title":"An observational study of cholecystectomy in patients receiving tegaserod","volume":"30","author":"Brinker","year":"2007","journal-title":"Drug Saf"},{"key":"10.1016\/j.cgh.2022.01.024_bib62","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1358\/dot.2004.40.12.872576","article-title":"Tegaserod: a serotonin 5-HT4 receptor agonist for treatment of constipation-predominant irritable bowel syndrome","volume":"40","author":"Cole","year":"2004","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.cgh.2022.01.024_bib63","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1111\/j.1572-0241.2004.30301.x","article-title":"Tegaserod does not alter fasting or meal-induced biliary tract motility","volume":"99","author":"Fisher","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.01.024_bib64","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1365-2036.2004.01864.x","article-title":"Systematic review: incidence of abdominal\/pelvic surgery amongst patients using tegaserod in randomized controlled trials","volume":"19","author":"Schoenfeld","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.01.024_bib65","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2165\/00002018-200427090-00001","article-title":"Safety profile of tegaserod, a 5-HT4 receptor agonist, for the treatment of irritable bowel syndrome","volume":"27","author":"Hasler","year":"2004","journal-title":"Drug Saf"},{"key":"10.1016\/j.cgh.2022.01.024_bib66","author":"Zelnorm"},{"key":"10.1016\/j.cgh.2022.01.024_bib69","article-title":"The 5-HT4 partial agonist, tegaserod, improves abdominal discomfort\/pain and normalizes altered bowel function in irritable bowel syndrome (IBS)","volume":"94","author":"Lefkowitz","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.01.024_bib70","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.14309\/ajg.0000000000001313","article-title":"Tegaserod for irritable bowel syndrome with constipation in women younger than 65 years without cardiovascular disease: pooled analyses of 4 controlled trials","volume":"116","author":"Shah","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.01.024_bib71","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0149-2918(02)85143-8","article-title":"Health-related quality of life associated with irritable bowel syndrome: comparison with other chronic diseases","volume":"24","author":"Frank","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.cgh.2022.01.024_bib72","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2036.2005.02577.x","article-title":"Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation","volume":"22","author":"Reilly","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.01.024_bib73","first-page":"S35","article-title":"Effectiveness of tegaserod therapy on GI-related resource utilization in a managed care population","volume":"11","author":"Stephenson","year":"2005","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.cgh.2022.01.024_bib74","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/ajg.2011.485","article-title":"IBS patients' willingness to take risks with medications","volume":"107","author":"Lacy","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.01.024_bib75","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/MCG.0b013e318189a7f9","article-title":"International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit","volume":"43","author":"Drossman","year":"2009","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cgh.2022.01.024_bib76","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1753-5174.2008.00012.x","article-title":"Exploratory study of tegaserod for dyspepsia in women receiving PPIs for heartburn","volume":"1","author":"Vakil","year":"2008","journal-title":"Arch Drug Inf"},{"key":"10.1016\/j.cgh.2022.01.024_bib77","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1053\/j.gastro.2006.11.002","article-title":"The serotonin signaling system: from basic understanding to drug development for functional GI disorders","volume":"132","author":"Gershon","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.01.024_bib78","doi-asserted-by":"crossref","first-page":"G260","DOI":"10.1152\/ajpgi.00056.2008","article-title":"Luminal regulation of normal and neoplastic human EC cell serotonin release is mediated by bile salts, amines, tastants, and olfactants","volume":"295","author":"Kidd","year":"2008","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.cgh.2022.01.024_bib79","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3389\/fpsyt.2020.00172","article-title":"The role of GI peptides in functional dyspepsia and gastroparesis: a systematic review","volume":"11","author":"Van den Houte","year":"2020","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.cgh.2022.01.024_bib80","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.gastro.2011.06.024","article-title":"Targeting serotonin synthesis to treat irritable bowel syndrome","volume":"141","author":"Tack","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.01.024_bib81","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2036.2012.05011.x","article-title":"Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders","volume":"35","author":"Tack","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.01.024_bib82","doi-asserted-by":"crossref","first-page":"224","DOI":"10.2174\/157015907782793621","article-title":"Human 5-HT(4) and 5-HT(7) receptor splice variants: are they important?","volume":"5","author":"Coupar","year":"2007","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.cgh.2022.01.024_bib83","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.lfs.2006.12.025","article-title":"Comparison of 5-HT4 and 5-HT7 receptor expression and function in the circular muscle of the human colon","volume":"80","author":"Irving","year":"2007","journal-title":"Life Sci"},{"key":"10.1016\/j.cgh.2022.01.024_bib84","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.phrs.2018.06.017","article-title":"What is the role of endogenous gut serotonin in the control of gastrointestinal motility?","volume":"140","author":"Keating","year":"2019","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.cgh.2022.01.024_bib95","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1046\/j.1365-2036.2001.01103.x","article-title":"Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects","volume":"15","author":"Degen","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.01.024_bib85","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/sj.bjp.0703615","article-title":"5-HT(4) receptors on cholinergic nerves involved in contractility of canine and human large intestine longitudinal muscle","volume":"131","author":"Prins","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cgh.2022.01.024_bib86","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1365-2982.2008.01223.x","article-title":"Distribution of serotonin receptors and interacting proteins in the human sigmoid colon","volume":"21","author":"Chetty","year":"2009","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.cgh.2022.01.024_bib87","doi-asserted-by":"crossref","first-page":"361","DOI":"10.5056\/jnm14157","article-title":"Distribution of 5-HT3, 5-HT4, and 5-HT7 receptors along the human colon","volume":"21","author":"Yaakob","year":"2015","journal-title":"J\u00a0Neurogastroenterol Motil"},{"key":"10.1016\/j.cgh.2022.01.024_bib96","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1185\/03007990802222832","article-title":"Tegaserod in patients with mechanical sensitivity and overlapping symptoms of functional heartburn and functional dyspepsia","volume":"24","author":"Miner","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.cgh.2022.01.024_bib97","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1111\/j.1572-0241.2006.00789.x","article-title":"Safety, tolerability, and efficacy of tegaserod over 13 months in patients with chronic constipation","volume":"101","author":"Muller-Lissner","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.01.024_bib88","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1016\/S0149-2918(03)80198-4","article-title":"Tegaserod maleate in the treatment of irritable bowel syndrome: a clinical review","volume":"25","author":"Rivkin","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.cgh.2022.01.024_bib89","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1177\/00912709922008524","article-title":"Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919)","volume":"39","author":"Zhou","year":"1999","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.cgh.2022.01.024_bib90","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1177\/0091270003251823","article-title":"Tegaserod pharmacokinetics are similar in patients with severe renal insufficiency and in healthy subjects","volume":"43","author":"Swan","year":"2003","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.cgh.2022.01.024_bib91","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/S0022-3565(24)36528-0","article-title":"SDZ HTF 919 stimulates canine colonic motility and transit in\u00a0vivo","volume":"280","author":"Nguyen","year":"1997","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.cgh.2022.01.024_bib92","first-page":"280","article-title":"The properties of a new prokinetically active drug, SDZ HTF 919 (abstract)","volume":"7","author":"Pfannkuche","year":"1995","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.cgh.2022.01.024_bib93","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/j.1552-4604.1997.tb04785.x","article-title":"First pharmacokinetic-pharmacodynamic study in humans with a selective 5-hydroxytryptamine4 receptor agonist","volume":"37","author":"Appel","year":"1997","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.cgh.2022.01.024_bib94","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S0009-9236(97)90050-3","article-title":"Clinical pharmacodynamics of SDZ HTF 919, a new 5-HT4 receptor agonist, in a model of slow colonic transit","volume":"62","author":"Appel","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.01.024_bib98","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1365-2982.2005.00715.x","article-title":"Effect of tegaserod on gut transit in male and female subjects","volume":"17","author":"Degen","year":"2005","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.cgh.2022.01.024_bib99","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1111\/j.1572-0241.2006.00708.x","article-title":"Modulation of intestinal gas dynamics in healthy human volunteers by the 5-HT receptor agonist tegaserod","volume":"101","author":"Coleski","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.01.024_bib100","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0016-5085(00)70251-4","article-title":"Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome","volume":"118","author":"Prather","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.01.024_bib101","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s12664-009-0048-6","article-title":"Effects of tegaserod and erythromycin in upper gut dysmotility: a comparative study","volume":"28","author":"Nasr","year":"2009","journal-title":"Indian J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.01.024_bib102","first-page":"A643","article-title":"Dose-dependent modulation of rectal afferent sensitivity by a 5-HT4 receptor agonist (abstract)","volume":"117","author":"Schikowski","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.01.024_bib103","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1443-9573.2005.00182.x","article-title":"Antinociceptive property of tegaserod in a rat model of chronic visceral hypersensitivity","volume":"6","author":"Liang","year":"2005","journal-title":"Chin J Dig Dis"},{"key":"10.1016\/j.cgh.2022.01.024_bib104","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2982.2005.00723.x","article-title":"Activation of peripheral 5-HT receptors attenuates colonic sensitivity to intraluminal distension","volume":"18","author":"Greenwood-Van Meerveld","year":"2006","journal-title":"Neurogastroenterol Motil"},{"issue":"19","key":"10.1016\/j.cgh.2022.01.024_bib105","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.3748\/wjg.v10.i19.2836","article-title":"Tegaserod inhibits noxious rectal distention induced responses and limbic system c-Fos expression in rats with visceral hypersensitivity","volume":"10","author":"Jiao","year":"2004","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.01.024_bib106","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1046\/j.1365-2982.2002.00328.x","article-title":"Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum","volume":"14","author":"Schikowski","year":"2002","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.cgh.2022.01.024_bib107","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1046\/j.1365-2036.2003.01449.x","article-title":"Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects","volume":"17","author":"Coffin","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.01.024_bib108","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1365-2982.2007.01030.x","article-title":"Sensory signalling effects of tegaserod in patients with irritable bowel syndrome with constipation","volume":"20","author":"Sabat\u00e9","year":"2008","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.cgh.2022.01.024_bib109","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1046\/j.1365-2036.2001.00925.x","article-title":"Review article: tegaserod","volume":"15","author":"Camilleri","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.01.024_bib110","first-page":"R143","article-title":"Preclinical and clinical effects of SDZ HTF 919, a new prokinetic drug, on colon transit (abstract)","volume":"353","author":"Appel","year":"1996","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"key":"10.1016\/j.cgh.2022.01.024_bib111","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1365-2982.2005.00681.x","article-title":"The effects of tegaserod, a 5-HT receptor agonist, on gastric emptying in a murine model of diabetes mellitus","volume":"17","author":"Crowell","year":"2005","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.cgh.2022.01.024_bib112","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1162\/1535350042973490","article-title":"Noninvasive assessment of gastric emptying by near-infrared fluorescence reflectance imaging in mice: pharmacological validation with tegaserod, cisapride, and clonidine","volume":"3","author":"Gremlich","year":"2004","journal-title":"Mol Imaging"},{"key":"10.1016\/j.cgh.2022.01.024_bib113","doi-asserted-by":"crossref","first-page":"G612","DOI":"10.1152\/ajpgi.00431.2003","article-title":"Regional gastric contractility alterations in a diabetic gastroparesis mouse model: effects of cholinergic and serotoninergic stimulation","volume":"287","author":"James","year":"2004","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.cgh.2022.01.024_bib114","doi-asserted-by":"crossref","first-page":"A752","DOI":"10.1016\/S0016-5085(98)83079-5","article-title":"Investigations on a 5HT4 agonist (SDZ HTF 919) and its main metabolite in conscious dogs: effects on gastrointestinal motility and impaired gastric emptying (abstract)","volume":"114","author":"Fioramonti","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.01.024_bib115","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1046\/j.1365-2036.2003.01775.x","article-title":"Influence of tegaserod on proximal gastric tone and on the perception of gastric distension","volume":"18","author":"Tack","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.01.024_bib116","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1111\/j.1365-2982.2010.01613.x","article-title":"Influence of tegaserod on proximal gastric tone and on the perception of gastric distention in functional dyspepsia","volume":"23","author":"Tack","year":"2011","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.cgh.2022.01.024_bib117","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1111\/j.1365-2036.2007.03521.x","article-title":"Clinical trial: effects of tegaserod on gastric motor and sensory function in patients with functional dyspepsia","volume":"26","author":"Thumshirn","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.01.024_bib118","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/BF02282320","article-title":"Omeprazole causes delay in gastric emptying of digestible meals","volume":"41","author":"Benini","year":"1996","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2022.01.024_bib119","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/gut.42.2.243","article-title":"Effect of gastric acid suppressants on human gastric motility","volume":"42","author":"Parkman","year":"1998","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2022.01.024_bib120","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1365-2036.2005.02528.x","article-title":"Omeprazole delays gastric emptying in healthy volunteers: an effect prevented by tegaserod","volume":"22","author":"Tougas","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.01.024_bib121","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.clpt.2005.02.002","article-title":"The use of tegaserod in critically ill patients with impaired gastric motility","volume":"77","author":"Banh","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.01.024_bib122","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1046\/j.1365-2036.2000.00854.x","article-title":"The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease","volume":"14","author":"Kahrilas","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.01.024_bib123","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/j.1365-2036.2006.03090.x","article-title":"The effects of tegaserod on oesophageal function and bolus transport in healthy volunteers: studies using concurrent high-resolution manometry and videofluoroscopy","volume":"24","author":"Fox","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.01.024_bib124","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.cgh.2006.01.014","article-title":"Effect of tegaserod on esophageal pain threshold, regurgitation, and symptom relief in patients with functional heartburn and mechanical sensitivity","volume":"4","author":"Rodriguez-Stanley","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.01.024_bib125","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1111\/j.1572-0241.2004.30301.x","article-title":"Tegaserod does not alter fasting or meal-induced biliary tract motility","volume":"99","author":"Fisher","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.01.024_bib126","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1542-3565(04)00356-8","article-title":"Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial","volume":"2","author":"Johanson","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.01.024_bib127","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/j.1572-0241.2005.40749.x","article-title":"Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study","volume":"100","author":"Kamm","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.01.024_bib128","first-page":"A20","article-title":"A\u00a0phase II placebo controlled randomized trial with tegaserod (T) in functional dyspepsia (FD) with normal gastric emptying (NGE) [abstract]","volume":"122","author":"Tack","year":"2002","journal-title":"Gasteroenterology"},{"key":"10.1016\/j.cgh.2022.01.024_bib129","doi-asserted-by":"crossref","first-page":"A54","DOI":"10.1016\/S0016-5085(03)80265-2","article-title":"Tegaserod improves gastric emptying in patients with gastroparesis and dyspeptic symptoms (abstract)","volume":"124","author":"Tougas","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.01.024_bib130","first-page":"1906","article-title":"Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials","volume":"103","author":"Vakil","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.01.024_bib131","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/s10620-009-1049-0","article-title":"Long-term tegaserod treatment for dysmotility-like functional dyspepsia: results of two identical 1-year cohort studies","volume":"55","author":"Chey","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2022.01.024_bib135","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/j.1572-0241.2002.05692.x","article-title":"Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms","volume":"97","author":"Fidelholtz","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.01.024_bib136","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1097\/MJT.0000000000000947","article-title":"Should we use tegaserod for irritable bowel syndrome?","volume":"26","author":"Marciniak","year":"2019","journal-title":"Am J Ther"},{"key":"10.1016\/j.cgh.2022.01.024_bib137","author":"Atkins"},{"key":"10.1016\/j.cgh.2022.01.024_bib138","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1365-2036.2006.02968.x","article-title":"Effects of a 5-HT(4) receptor agonist on oesophageal function and gastro-oesophageal reflux: studies using combined impedance-manometry and combined impedance-pH","volume":"24","author":"Tutuian","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.01.024_bib139","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1365-2982.2007.00944.x","article-title":"Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT4 agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trial","volume":"19","author":"Foxx-Orenstein","year":"2007","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.cgh.2022.01.024_bib140","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/j.1440-1746.2006.04543.x","article-title":"Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome","volume":"22","author":"Harish","year":"2007","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.01.024_bib141","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1111\/j.1572-0241.2007.01336.x","article-title":"Effect of tegaserod on recto-sigmoid tonic and phasic activity in constipation-predominant irritable bowel syndrome","volume":"102","author":"Di Stefano","year":"2007","journal-title":"Am J Gastroenterol"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356522000787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356522000787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:40:00Z","timestamp":1761543600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356522000787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":136,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1542356522000787"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2022.01.024","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tegaserod: What\u2019s Old Is New Again","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2022.01.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the AGA Institute","name":"copyright","label":"Copyright"}]}}